Manipal Hospitals
| India | Turkey | Austria | |
| NanoKnife | from $8,500 | from $9,500 | from $25,000 |
| CyberKnife | from $6,000 | from $4,750 | from $50,000 |
| Actinium-225 Therapy | from $8,500 | from $22,955 | from $55,000 |
| Enucleation of tumor on pancreas | from $5,500 | from $10,000 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Pancreatic neuroendocrine tumors treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Pancreatic neuroendocrine tumors treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Pancreatic neuroendocrine tumors treatment journey.
Dr. Shruti Kate specializes in pancreatic neuroendocrine tumors, trained at Tata Memorial Hospital – one of India's top cancer centers.
Performed 50,000+ cancer surgeries over 30 years of experience – Dr. Nagarkar focuses on both curing patients and improving their quality of life.
Dr. Shaunak specializes in targeted therapies for pancreatic neuroendocrine tumors, with research presented at the elite Gastrointestinal Cancer Symposium.
Dr. Sridhar specializes in radiotherapy for pancreatic neuroendocrine tumors at HCG Manavata Cancer Centre, with extensive training in radiation oncology.
Pancreatic neuroendocrine tumors (pNETs) originate in hormone-producing cells, whereas standard pancreatic cancer arises from enzyme-producing cells. pNETs usually grow slower and offer better survival rates. Indian hospitals utilize specialized tools like Ga-68 DOTATATE PET-CT scans and Lu-177 PRRT to target these specific islet cell tumors.
Bookimed Expert Insight: While standard pancreatic cancer requires immediate aggressive surgery, pNET treatment in India focuses on tumor biology. Data shows that specialized centers like HCG Manavata utilize NanoKnife technology, costing around $8,500 to $14,500, for tumors near sensitive vessels where traditional surgery might be too risky. This tech-driven precision allows for treating complex cases that other regions might consider inoperable.
Patient Consensus: Patients emphasize that pNETs are unique and require checking specific details like the Ki-67 index and grade before starting treatment. They often note that a generic cancer diagnosis can change after a specialized pathology review at large Indian tertiary centers.
Indian hospitals offer surgical options for pancreatic neuroendocrine tumors (pNETs) ranging from organ-sparing enucleation to radical resections. Specialists use robotic systems and laparoscopic techniques to preserve pancreatic function. Choice depends on tumor size, type, and location within the organ.
Bookimed Expert Insight: While many hospitals focus on traditional surgery, Dr. Rela Institute & Medical Centre utilizes the Da Vinci robotic system for high-precision pancreatic resections. This technology is particularly effective for organ-sparing procedures like enucleation. Packages for enucleation in India range from $5,500 to $10,500. This is approximately 70% lower than costs in Western Europe or the US for the same robotic approach.
India uses advanced non-surgical treatments for metastatic pancreatic neuroendocrine tumors (pNETs) like Peptide Receptor Radionuclide Therapy (PRRT). Experts apply 177Lu-DOTATATE and 225Ac-DOTATOC to target cancer cells. Facilities also offer CyberKnife radiosurgery and Targeted Alpha Therapy to treat complex cases without invasive surgery.
Bookimed Expert Insight: Indian oncology centers like HCG Manavata provide a unique concentration of expertise in both nuclear medicine and clinical research. Our data shows specialists like Dr. Raj Nagarkar have participated in over 200 clinical trials. This research focus means patients often access the latest dosing protocols for targeted therapies like immunotherapy and metronomic therapy sooner than at general hospitals.
Five-year survival rates for pancreatic neuroendocrine tumors (pNETs) in India range from 40% to 60% overall. Localized tumors show excellent outcomes with 83% to 90% survival. Advanced multidisciplinary centers like Manipal Hospitals and HCG Manavata provide specialized surgical and nuclear medicine interventions.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator for complex pNET care. Manipal Hospitals treats 2,000,000 patients annually across 15 facilities. High-volume centers often demonstrate better surgical outcomes. Dr. Chaitainya Borde at HCG Manavata has managed 30,000+ PET scans. This volume suggests high diagnostic accuracy for staging.
Patient Consensus: Patients emphasize that long-term survival requires ongoing monitoring even after surgery. Success is often viewed as maintaining a good quality of life while managing the tumor as a chronic condition.
Top Indian hospitals for pancreatic neuroendocrine tumors (pNETs) include Manipal Hospitals, Dr. Rela Institute, and HCG Manavata Cancer Centre. These centers provide infrastructure like Ga-68 DOTATATE PET-CT scans for precise tumor mapping. Specialized nuclear medicine departments offer Lu-177 and Actinium-225 therapies for advanced cases.
Bookimed Expert Insight: While many seek care in New Delhi or Mumbai, Nashik has emerged as a specialized hub with HCG Manavata Cancer Centre. This facility has managed over 30,000 PET scans and provides rare Actinium-225 therapy. Dr. Chaitainya Borde at this center has treated 1,000+ patients, offering high-volume expertise outside the major metro capitals.
Patient Consensus: Patients emphasize finding a dedicated pancreatic surgeon rather than a general oncologist. They also stress that confirming your Ki-67 grading and proper tumor classification is vital before starting any treatment.
Specialists in India manage pancreatic neuroendocrine tumour side effects. They use oncology-led supportive care, tailored dieting, and nuclear medicine protocols. Centres like HCG Manavata Cancer Centre use targeted therapies and PRRT (Lutetium-177). They provide dedicated aftercare to minimise fatigue and abdominal distress. Multi-disciplinary teams provide specific medications for gastrointestinal symptoms and hormonal imbalances.
Bookimed Expert Insight: Indian cancer centres often have higher patient volumes than Australian facilities. For example, HCG Manavata Cancer Centre alone performs 65,000 cancer surgeries. This high volume means their medical oncologists, such as Dr Shruti Kate, have extensive experience. They manage specific, paradoxical side effects of lanreotide and metronomic therapies. These are rarely encountered in less specialised centres.
Patient Consensus: Patients note that somatostatin injections can cause unexpected itching. They recommend slow administration to reduce pain. They highlight the benefits of resting after PRRT. Using CBD for nausea or appetite loss also helps. These practices significantly improve the recovery experience in India.
Treatment for pancreatic neuroendocrine tumours in India depends on whether the disease is localised or metastatic. For localised cases, it centres on surgical resection. For metastatic disease, it focuses on nuclear medicine. Specialists use the Whipple procedure, distal pancreatectomy, and enucleation. Other options include PRRT (Peptide Receptor Radionuclide Therapy) and targeted therapies. Examples include everolimus and sunitinib.
Bookimed Expert Insight: India provides a distinct advantage for advanced cases through high-volume nuclear medicine departments. For instance, Dr Chaitainya Borde at HCG Manavata has managed 30,000+ PET scans. He specialises in Lu-177 therapies. Australian patients can access these radionuclide treatments at centres serving over 75,000 patients annually. They often provide significantly shorter PRRT waiting times compared to domestic public systems.
Patient Consensus: Patients emphasise that determining if a tumour is operable is the first priority. They note that Ga-68 DOTATATE scans are essential in India. These scans confirm if PRRT will be effective for advanced disease.
Surgery for pancreatic neuroendocrine tumours in India is highly effective. Tertiary centres report outcomes matching international standards for localised cases. JCI-accredited facilities use robotic systems and parenchyma-sparing techniques like enucleation. These methods provide a potential cure while preserving organ function.
Bookimed Expert Insight: Quality markers in India align closely with Western standards. Manipal Hospitals serves patients from 30 countries and holds JCI accreditation. Dr Raj Nagarkar at HCG Manavata holds an MRCS from Edinburgh. These international qualifications mean Australian patients receive care regulated by familiar surgical standards.
Patient Consensus: Surgery offers the best chance for a cure when tumours are caught early. Patients in India appreciate that PNETs grow slower than common pancreatic cancers. This often leads to better long-term survival after successful removal.
PRRT is available in India for inoperable or metastatic pancreatic neuroendocrine tumours (PNETs). Specialist centres use Lutetium-177 (Lu-177) DOTATATE to target somatostatin receptors. Patients typically undergo 4 cycles spaced 8 weeks apart at JCI-accredited facilities.
Bookimed Expert Insight: India ranks globally in complex oncology. Its nuclear medicine facilities offer an experience advantage. Dr Chaitainya Borde at HCG Manavata has performed over 1,000 radionuclide therapies. This high volume often leads to more refined dosing protocols for patients with complex metastatic PNETs.
Patient Consensus: Patients in India find PRRT highly effective for well-differentiated tumours. They often report only mild fatigue for a few days. They emphasise that confirmed DOTATATE-PET avidity is the critical first step before travel.
Metastatic pancreatic neuroendocrine tumours are treated in India using therapies like Lu-177 PRRT and CyberKnife radiosurgery. Major oncology centres in Bengaluru, Chennai, and Nashik provide multidisciplinary care for stage IV cases. Treatment often includes targeted medications, liver-directed therapies, and nuclear medicine.
Bookimed Expert Insight: Indian oncology centres often offer Actinium-225 therapy and NanoKnife alongside standard PRRT. This provides options for patients who do not respond to drug-based treatments. HCG Manavata Cancer Centre has also conducted over 200 clinical trials. This indicates high-level research access for rare metastatic tumour subtypes.
Patient Consensus: Patients in India emphasise getting genomic testing and Ki-67 pathology details early. This helps specialists match specific mutations to targeted therapies or PRRT eligibility.
Pancreatic neuroendocrine tumours (PNETs) arise from hormone-producing islet cells. They usually grow slower than typical pancreatic cancer. In contrast, typical pancreatic cancer originates in ductal cells, representing over 95% of cases. PNETs generally offer a better prognosis and higher 5-year survival rates.
Bookimed Expert Insight: Indian centres like HCG Manavata Cancer Centre offer nuclear medicine therapies including Actinium-225 and Lu-177. These specific treatments target PNET receptors and are not typically used for common pancreatic adenocarcinoma. This highlights why an accurate subtype diagnosis is vital for choosing the correct therapy path.
Patient Consensus: Patients often feel relieved to learn PNETs are a distinct disease. They are more survivable than typical pancreatic cancer. They emphasise the importance of checking the Ki-67 index. They also advise getting a DOTATATE PET scan in India. This scan confirms if the tumour is slow-growing.
Treatment for pancreatic neuroendocrine tumours in India requires a multidisciplinary team. This team is led by surgical and medical oncologists. Specialists at large tertiary centres use CyberKnife, NanoKnife, and Actinium-225 therapy. These centres include Manipal Hospitals and HCG Manavata Cancer Centre. These teams include subspecialists in nuclear medicine, endocrinology, and hepatopancreatobiliary surgery.
Bookimed Expert Insight: Patients should prioritise centres with integrated nuclear medicine departments for more accurate staging. Data shows specialists like Dr Chaitainya Borde at HCG Manavata have performed over 30,000 PET scans. This volume is critical. Identifying somatostatin receptors via Gallium-68 PET-CT shows if treatments like Lu-177 are suitable.
Patient Consensus: Patients in India recommend seeing a neuroendocrine tumour specialist first rather than a general oncologist. They suggest making sure the hospital can perform Gallium PET scans and PRRT before starting any treatment.
Patients with low-grade pancreatic neuroendocrine tumours in India see 5-year survival rates exceeding 80–90% after surgery. Outcomes depend heavily on tumour grade rather than just the stage. Modern therapies such as Lu-177 radionuclides and robotic surgery significantly extend survival for advanced cases.
Bookimed Expert Insight: Indian oncology centres often provide a higher level of sub-specialisation than patients expect. For example, HCG Manavata Cancer Centre has handled over 100,000 international patients. It also features a US-FDA audited research institute. This high volume lets specialists like Dr Chaitainya Borde manage 30,000+ PET scans. That leads to much higher diagnostic accuracy for rare neuroendocrine cases.
Patient Consensus: Patients in India find that well-differentiated tumours behave less aggressively than standard pancreatic cancer. They often achieve long-term stability with somatostatin analogues. They report that even liver metastases can be managed for decades with the right sequence of treatments.